Evidence map›Paper›PMID 42472920›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026

Association between disease duration, severity, and treatment outcome of office-based blue laser therapy for benign vocal fold lesions.

Abdul-Latif Hamdan, Ghena Lababidi, Lana Ghzayel, Valerie Sarkis, Patrick Abou Raji Feghali, Ibana Carapiperis, Elie Alam, Marc Mourad, Jerome R Lechien

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abdul-Latif HamdanDepartment of Otolaryngology - Head and Neck Surgery, American University of Beirut Medical Center, Riad El Solh, 1107 2020, Beirut, 11-0236, Lebanon. ah77@aub.edu.lb.ORCID http://orcid.org/0000-0003-1493-3568
Ghena LababidiDepartment of Otolaryngology - Head and Neck Surgery, American University of Beirut Medical Center, Riad El Solh, 1107 2020, Beirut, 11-0236, Lebanon.
Lana GhzayelDepartment of Otolaryngology - Head and Neck Surgery, American University of Beirut Medical Center, Riad El Solh, 1107 2020, Beirut, 11-0236, Lebanon.
Valerie SarkisDepartment of Otolaryngology - Head and Neck Surgery, American University of Beirut Medical Center, Riad El Solh, 1107 2020, Beirut, 11-0236, Lebanon.
Patrick Abou Raji FeghaliDepartment of Otolaryngology - Head and Neck Surgery, American University of Beirut Medical Center, Riad El Solh, 1107 2020, Beirut, 11-0236, Lebanon.
Ibana CarapiperisDepartment of Otolaryngology - Head and Neck Surgery, American University of Beirut Medical Center, Riad El Solh, 1107 2020, Beirut, 11-0236, Lebanon.
Elie AlamDepartment of Otolaryngology - Head and Neck Surgery, American University of Beirut Medical Center, Riad El Solh, 1107 2020, Beirut, 11-0236, Lebanon.
Marc MouradDepartment of Otolaryngology - Head and Neck Surgery, American University of Beirut Medical Center, Riad El Solh, 1107 2020, Beirut, 11-0236, Lebanon.
Jerome R LechienDepartment of Otolaryngology-Head and Neck Surgery, School of Medicine, Foch Hospital, University Paris Saclay, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo analyze whether disease duration and severity can predict voice quality improvement following office-based blue laser therapy (OBLT) for benign lesions of the vocal folds. STUDY

designRetrospective chart review.

methodsMedical records of patients with benign lesions of the vocal folds who underwent OBLT between November 2023 and December 2025 were reviewed. Demographic data included age, gender, history of smoking, reflux disease, voice abuse, diagnosis, follow-up period, and disease duration. Self-perceived disease severity was assessed using the Voice Handicap Index-10 (VHI-10) and the Visual Analog Scale (VAS). Secondary outcome measures included acoustic and aerodynamic parameters.

resultsSixty patients were included (35 females, mean age: 52.35 ± 14.45). The mean disease duration was 15.35 ± 20.80 months. Linear regression analysis showed no association between disease duration and mean change in VHI-10 (r = 0.018, p = 0.901) or VAS scores (r = 0.021, p = 0.886). There was a strong significant association between pre-operative VHI-10 score and mean change in VHI-10 (r = 0.681, p < 0.001) and the mean change in VAS scores (r = 0.636, p < 0.001), and between pre-operative VAS scores and mean change in VHI-10 (r = 0.642, p < 0.001) and the mean change in VAS scores (r = 0.758, p < 0.001). A weak positive significant association was found between pre-operative VAS scores and mean change in percent jitter (r = 0.271, p = 0.040). No significant associations were observed between disease duration, disease severity, and other acoustic or aerodynamic parameters.

conclusionDisease severity and not disease duration was associated with self-perceived improvement in voice quality following office-based blue laser therapy for benign vocal fold lesions.

Indexed as

Laryngeal DiseasesLaser TherapyVocal CordsAdultAgedBlue LightFemaleHumansMaleMiddle AgedRetrospective StudiesSeverity of Illness IndexTime FactorsTreatment OutcomeVoice QualityBenign lesionsBlue laserDysphoniaOffice-basedVHI-10; voice; otolaryngology

Identifiers

PMID42472920

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.